Scandinavian ChemoTech has been notified that the patent authority in the US has approved the Company's patent relating to the unique IQwave™, vetIQure™, probe and the unique electrodes that the TSE™ treatment kit consists of. The approved patent protects both the unique probe, which the doctor and veterinarian hold, as well as the unique electrodes (needles) that are used to deliver the dynamic and tumour specific pulse in the treatment of patients. The probe has unique properties that allow the user to adjust how large of an area that is subject for treatment.

Since the electrodes can be attached in various configurations in the same probe, Scandinavian ChemoTech can create significant cost benefits for healthcare providers. This is because the clinics do not have to buy several different accessories to be able to carry out the TSE treatments. This applies to both the company's Human Care and Animal Care operations.

The innovators behind this patent are Mohan Frick, Bertil Persson and Johan Marnfeldt.